Value AD
CAN BE
ALTERNATIVE
INVESTMENT
Synthesis and Biological Activity Assessment of Different Diastereomers in siRNA Drug LEQVIO (Inclisiran) (U01) Clinical Trial Not Allowed
FOR-FD-24-007
Terrin Brown Grantor
Funding Opportunity Number: FOR-FD-24-007
Opportunity Category: Discretionary
Expected Number of Awards: 1
CFDA Number(s): 93.103 -- Food and Drug Administration Research
Cost Sharing or Matching Requirement: No
Posted Date: Nov 24, 2023 12:00:00 AM EST
Closing Date: N/A
Award Ceiling: $300000
Award Floor: $300000
Eligible Applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification),Special district governments,City or township governments,Independent school districts,State governments,Private institutions of higher education,Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility",Native American tribal organizations (other than Federally recognized tribal governments),Native American tribal governments (Federally recognized),Small businesses,For profit organizations other than small businesses,Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education,Public housing authorities/Indian housing authorities,Public and State controlled institutions of higher education,Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education,County governments
Additional Information on Eligibility: Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The FDA will not accept duplicate or highly overlapping applications under review at the same time per 2.3.7.4 Submission of Resubmission Application. This means that the NIH or FDA will not accept:•A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.•A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application.•An application that has substantial overlap with another application pending appeal of initial peer review (see 2.3.9.4 Similar, Essentially Identical, or Identical Applications).
Description:
The purpose of this research is to systematically evaluate the diastereomeric composition of LEQVIO (Inclisiran), an FDA-approved, N-acetyl galactosamine (GalNAc)-conjugated siRNA drug, and to understand the biological/pharmacological activity of each diastereomer in LEQVIO through stereo chemically controlled synthesis and biological activity assessment using in vitro and animal models. The proposed studies will focus on 1) synthesis of each diastereomer of LEQVIO (Inclisiran) in stereo chemically pure form; 2) assessment of the biological activity of each stereo chemically pure diastereomer in inhibiting PCSK9 activity using in vitro assays and in a transgenic mouse model; 3) development of analytical methods to identify and characterize the stereochemical structure of each diastereomer in LEQVIO; and 4) assessment of the individual contribution of each diastereomer to the overall pharmacological activity of LEQVIO. Tools developed in this research can also be applied to other similar GalNAc-conjugated siRNAs specifically, and other siRNAs in general. Knowledge gained from this research will also contribute to the sameness evaluation of generic siRNAs, and to the quality control of oligonucleotide drugs.
